Technical Analysis for TPTX - Turning Point Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
36.89 | 0.03% | 0.01 |
TPTX closed up 0.03 percent on Friday, October 11, 2019, on 70 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Flat |
| See historical TPTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 0.03% | |
| Oversold Stochastic | Weakness | 0.03% | |
| Wide Bands | Range Expansion | 3.89% | |
| Oversold Stochastic | Weakness | 3.89% | |
| Stochastic Reached Oversold | Weakness | 1.49% | |
| Wide Bands | Range Expansion | 1.49% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Medicine Cancer Chemical Compounds Treatment Of Cancer Oncology Solid Tumors Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Cancer Therapies Targeted Therapy Pyrrolidines Signal Transduction Protein Kinase Inhibitors Kinase
Medicine Cancer Chemical Compounds Treatment Of Cancer Oncology Solid Tumors Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Cancer Therapies Targeted Therapy Pyrrolidines Signal Transduction Protein Kinase Inhibitors Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more TPTX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 58.56 |
| 52 Week Low | 24.21 |
| Average Volume | 259,157 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 43.2767 |
| 20-Day Moving Average | 38.7435 |
| 10-Day Moving Average | 37.057 |
| Average True Range | 2.7263 |
| ADX | 21.66 |
| +DI | 14.6651 |
| -DI | 19.2908 |
| Chandelier Exit (Long, 3 ATRs ) | 37.7211 |
| Chandelier Exit (Short, 3 ATRs ) | 43.6789 |
| Upper Bollinger Band | 43.7557 |
| Lower Bollinger Band | 33.7313 |
| Percent B (%b) | 0.32 |
| BandWidth | 25.873759 |
| MACD Line | -2.1133 |
| MACD Signal Line | -2.1394 |
| MACD Histogram | 0.0261 |
| Fundamentals | Value |
|---|---|
| Market Cap | 595.92 Million |
| Num Shares | 16.2 Million |
| EPS | -1.33 |
| Price-to-Earnings (P/E) Ratio | -27.76 |
| Price-to-Sales | 0.85 |
| Price-to-Book | 1.17 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 39.55 | ||||
| Resistance 3 (R3) | 39.59 | 38.75 | 39.10 | ||
| Resistance 2 (R2) | 38.75 | 38.07 | 38.73 | 38.95 | |
| Resistance 1 (R1) | 37.82 | 37.66 | 37.40 | 37.78 | 38.81 |
| Pivot Point | 36.98 | 36.98 | 36.77 | 36.96 | 36.98 |
| Support 1 (S1) | 36.05 | 36.30 | 35.63 | 36.01 | 34.97 |
| Support 2 (S2) | 35.21 | 35.89 | 35.19 | 34.83 | |
| Support 3 (S3) | 34.28 | 35.21 | 34.68 | ||
| Support 4 (S4) | 34.24 |
